Antibody Discovery News and Research

RSS

Unexpected antibody discovery provides new insight into how the body responds to malaria infection

Malaria, a pathogen transmitted into blood by mosquitoes in tropical climates, is typically thought of as a blood and liver infection.

3 Nov 2021

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

In an article published in the open-access journal Advance Engineering, a multinational team of researchers reported the selection and characterization of 3 potent SARS-CoV-2 antibodies - S-E6, S-B8, and S-D4 - from a pre-COVID-19 human combinatorial antibody library that was established 20 years ago.

3 Nov 2021

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Sphere Fluidics announced today that it has closed a $40 million (circa £30 million) investment round.

From Sphere Fluidics 28 Oct 2021

Antibody validation and rapid peptide mapping technology

In this interview, News-Medical speaks to Bin Ma, President of Rapid Novor, about antibody validation and rapid peptide mapping technology.

From Rapid Novor Inc 11 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

A World First: sequencing polyclonal antibodies using only proteomics

News-Medical speaks to Bin Ma, President of Rapid Novor, about their latest research that sequenced polyclonal antibodies using only proteomics.

From Rapid Novor Inc 21 Jun 2021

Researchers develop rapid antibody screening method for novel COVID-19 therapeutics development

New research undertaken by researchers in the USA describes two parallel but distinct in vivo approaches for the accelerated discovery of antibodies targeting SARS-CoV-2 spike protein.

3 Jun 2021

Rapid Novor First to Decode Polyclonal Antibodies Using Only Proteomics

Novel antibody discovery platform REpAb® unlocks direct access to key antibodies through next-generation protein sequencing

From Rapid Novor Inc 27 May 2021

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

In a new study, researchers used an antibody discovery technology to identify a new potently neutralizing antibody with a unique mode of SARS-CoV-2 recognition. They reported their results on the bioRxiv preprint server.

18 May 2021

Sphere Fluidics announces enhanced Cyto-Mine capability and performance

Sphere Fluidics, a company developing single-cell analysis systems, today announced it has enhanced the performance of its Cyto-Mine® System.

From Sphere Fluidics 17 May 2021

SwiftScale Biologics: Cell-Free Synthesis of Biologics

In this interview, News-Medical talks to David Mace, CEO at SwiftScale Biologics, about the work they do in cell-free synthesis, their partnership with Sartorius and the biologics field as a whole.

From Sartorius 30 Mar 2021

Study shows substantial benefit of combination therapy for advanced Marburg infections

A new study conducted at the Galveston National Laboratory at the The University of Texas Medical Branch at Galveston has shown substantial benefit to combining monoclonal antibodies and the antiviral remdesivir against advanced Marburg virus.

25 Mar 2021

Researchers present fragment-based computational design of antibodies that target structured epitopes

A new study describes a novel fragment-based method to design antibody complementarity determining region (CDR) loops.

8 Mar 2021

Are antibody cocktails the key to COVID-19 treatment?

News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.

18 Feb 2021

Second-generation double antibody protects from SARS-CoV-2 and its tested variants

The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation 'double antibody' that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants. It also prevents the virus from mutating to resist the therapy.

24 Jan 2021

OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins

OXGENE™ announces the introduction of its self-labelling integral membrane (SLIM™) protein discovery system.

12 Jan 2021

Research at Advanced Photon Source laid the groundwork for effective COVID-19 vaccines

There is light at the end of the COVID-19 pandemic tunnel. Several vaccines against the SARS-CoV-2 virus that causes COVID-19 are now in clinical trials, with one -- developed by Pfizer/BioNTech -- already having been approved for emergency use in the United States.

18 Dec 2020

Eureka's InvisiMask human antibody nasal spray offers protection against SARS-CoV-2 in mice

Eureka Therapeutics, Inc. announced today successful preclinical results from its InvisiMask™ Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours.

14 Dec 2020

£453,000 grant awarded to boost research and development for COVID-19 antibodies

Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, leader in innovation and impact, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts.